Hepion Pharmaceuticals, Inc. (HEPA)
Data as of , from SEC Form 4 filings.
See up to 3 months of HEPA. The 7-day demo opens the 1M and 3M ranges and puts HEPA on your watchlist.
Start 7-day demoLatest HEPA insider trades
About Hepion Pharmaceuticals, Inc. (HEPA)
Hepion Pharmaceuticals, Inc. files with the SEC under CIK 0001583771 and is classified as pharmaceutical preparations. We track it alongside the rest of the Health Care sector.
HEPA Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 15 | 45,900,000 | $835K |
| Grant or award | 8 | 6,578,000 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
HEPA insider transactions (Form 4)
2819 Form 4 filings on record, the earliest from Apr 27, 2026, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Danina Fisher - Director | Open-market purchase | Common Stock | 200,000 | $0.05 | $10K | |
| Danina Fisher - Director | Open-market purchase | Warrants | 200,000 | $0.00 | - | |
 Vincent S. Lopriore - Officer | Open-market purchase | Warrants | 12,500,000 | $0.00 | - | |
 Michael J. Purcell - Director | Grant or award | Stock Options | 299,000 | $0.00 | - | |
 Gary S. Stetz - Officer | Grant or award | Stock Options | 1,345,500 | $0.00 | - | |
| Vincent S. Lopriore - Officer | Grant or award | Stock Options | 1,345,500 | $0.00 | - | |
| Chase Lopriore - Officer | Grant or award | Stock Options | 1,345,500 | $0.00 | - | |
| Danina Fisher - Director | Grant or award | Stock Options | 299,000 | $0.00 | - | |
 James Gordon Liddy - Director | Grant or award | Stock Options | 299,000 | $0.00 | - | |
| Sireesh Appajosyula - Officer | Grant or award | Stock Options | 1,345,500 | $0.00 | - | |
| Gary S. Stetz II - Director | Grant or award | Stock Options | 299,000 | $0.00 | - | |
| Gary S. Stetz II - Director | Open-market purchase | Common Stock | 500,000 | $0.05 | $25K | |
| Gary S. Stetz II - Director | Open-market purchase | Warrants | 500,000 | $0.00 | - | |
| Gary S. Stetz - Officer | Open-market purchase | Common Stock | 2,000,000 | $0.05 | $100K | |
| Gary S. Stetz - Officer | Open-market purchase | Warrants | 2,000,000 | $0.00 | - | |
| Michael J. Purcell - Director | Open-market purchase | Common Stock | 2,000,000 | $0.05 | $100K | |
| Michael J. Purcell - Director | Open-market purchase | Warrants | 2,000,000 | $0.00 | - | |
| Sireesh Appajosyula - Officer | Open-market purchase | Common Stock | 2,000,000 | $0.05 | $100K | |
| Sireesh Appajosyula - Officer | Open-market purchase | Warrants | 2,000,000 | $0.00 | - | |
| Vincent S. Lopriore - Officer | Open-market purchase | Common Stock | 8,000,000 | $0.05 | $400K | |
| Vincent S. Lopriore - Officer | Open-market purchase | Common Stock | 2,000,000 | $0.05 | $100K | |
| Vincent S. Lopriore - Officer | Open-market purchase | Warrants | 8,000,000 | $0.00 | - | |
| Vincent S. Lopriore - Officer | Open-market purchase | Warrants | 2,000,000 | $0.00 | - | |
| Michael J. Purcell - Director | Open-market purchase | Common Stock, par value $0.0001 per share | 1,250,000 | $0.04 | $50K | |
| Vincent S. Lopriore - Officer | Open-market purchase | Common Stock, par value $0.0001 per share | 5,000,000 | $0.04 | $200K | |
| Vincent S. Lopriore - Officer | Open-market purchase | Common Stock, par value $0.0001 per share | 1,250,000 | $0.04 | $50K | |
| Sireesh Appajosyula - Director | Open-market purchase | Common Stock, par value $0.0001 per share | 1,250,000 | $0.04 | $50K | |
| Gary S. Stetz - Officer | Open-market purchase | Common Stock, par value $0.0001 per share | 1,250,000 | $0.04 | $50K |
HEPA insider trading FAQ
What is the latest insider trade for HEPA?
Hepion Pharmaceuticals, Inc. (HEPA) had 15 insider filings in the last 90 days, with the most recent on 2026-10-02. The full record for HEPA runs to 19 Form 4 filings, the earliest from 2026-04-27. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying HEPA stock?
15 insider purchases of HEPA were filed in the last 90 days, totaling $835K.
How many insiders are selling HEPA stock?
No insider sales of HEPA were filed in the last 90 days.
Where can I see HEPA SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects HEPA Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Danina Fisher view on EDGAR
- - Vincent S. Lopriore view on EDGAR
- - Michael J. Purcell view on EDGAR
- - Gary S. Stetz view on EDGAR
- - Vincent S. Lopriore view on EDGAR
- - Chase Lopriore view on EDGAR
- - Danina Fisher view on EDGAR
- - James Gordon Liddy view on EDGAR
- - Sireesh Appajosyula view on EDGAR
Related companies with recent insider activity
Learn more
- How to read insider buying signals
- What an open-market purchase by an insider can and cannot tell you.
- Insider activity in Health Care
- Where HEPA's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow HEPA with a 7-day demo
- HEPA on your watchlist
- Every HEPA Form 4 filing on record
- Up to 3 months of HEPA price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
